Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 21, 2005; 11(23): 3644-3646
Published online Jun 21, 2005. doi: 10.3748/wjg.v11.i23.3644
Published online Jun 21, 2005. doi: 10.3748/wjg.v11.i23.3644
Table 1 Recurrence time of TACE group and control group.
| Study group (987 patients) | Control group (643 patients) | |||||||
| Recurrence time (mo) | 6 | 12 | 18 | >24 | 6 | 12 | 18 | >24 |
| Recurrence cases | 219 | 770 | 874 | 987 | 396 | 480 | 515 | 643 |
| Recurrence rate (%) | 22.2 | 78.0 | 88.6 | 100 | 61.6 | 74.7 | 80.1 | 100 |
| Disease-free cases | 768 | 217 | 113 | 0 | 247 | 163 | 128 | 0 |
| Non-recurrence rate | 77.8 | 22.0 | 11.4 | 0 | 38.4 | 25.3 | 19.9 | 0 |
- Citation: Cheng HY, Wang X, Chen D, Xu AM, Jia YC. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. World J Gastroenterol 2005; 11(23): 3644-3646
- URL: https://www.wjgnet.com/1007-9327/full/v11/i23/3644.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i23.3644